Task-related EEG activation as a biomarker for early Alzheimer's Disease

任务相关脑电图激活作为早期阿尔茨海默病的生物标志物

• 批准号: 9903186
• 负责人: Matthew Euler
• 金额: $ 15.25万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9903186
• 关键词: Address; Affect; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer’s disease biomarker; American; Amyloid; Attention; Behavior; Behavioral; Biological Markers; Clinical Trials; Cognitive; Complex; Detection; Development; Diagnostic; Disease; Early Diagnosis; Early identification; Elderly; Electrodes; Electroencephalography; Exertion; Exhibits; Face; Female; Functional Magnetic Resonance Imaging; Goals; Healthcare; Hour; Impaired cognition; Individual; Lead; Link; Long-Term Care; Measures; Memory; Methods; Mission; National Institute on Aging; Neurologic; Neuropsychology; Outcome Measure; Participant; Performance; Psyche structure; Punishment; Research; Resources; Rest; Scalp structure; Signal Transduction; Spinal Puncture; Staging; Task Performances; Techniques; Technology; advanced disease; amnestic mild cognitive impairment; care costs; cingulate cortex; cognitive skill; comparative; cost; cost effectiveness; early detection biomarkers; efficacy clinical trial; human old age (65+); improved; in vivo; indexing; instrumental activity of daily living; mild cognitive impairment; neuroimaging; neurotransmission; novel marker; pre-clinical; recruit; relating to nervous system; screening; skills; tau Proteins

Project Summary/Abstract The primary goal of this project is to examine a specific form of task-related EEG activity, as a potential novel biomarker for early Alzheimer’s disease. Despite recent progress in developing biomarkers for Alzheimer’s disease, the existing suite of measures faces limitations related to invasiveness, cost, high technological demands, and low accessibility. To help address these challenges, this project will investigate EEG mid-frontal theta power (MFT), as a potentially inexpensive, non-invasive, and easily-implemented alternative. It is proposed that because Alzheimer’s disease involves the loss of cognitive and neural reserve, individuals in early stages should require increased mental exertion to achieve a given level of task performance. In turn, EEG MFT has been strongly linked to mental exertion, and as such may be over-activated in early Alzheimer’s stages. To assess the potential of MFT as a biomarker of mental exertion in early Alzheimer’s disease, this project will recruit three groups of older adults (n = 40 each; 65 years-old or older; 50% female) who are either cognitively-intact, or meet diagnostic criteria for amnestic Mild Cognitive Impairment or early Alzheimer’s disease. The first Aim of the project is to examine differences in MFT across these three groups, while controlling for differences in task performance. The second Aim of the project is to examine the sensitivity of MFT to deficits in specific cognitive and functional skills that tend to be affected in earlier disease stages. To achieve these Aims, participants will complete a single, three-hour study session, involving a brief diagnostic battery, assessments of cognitive and functional skills (instrumental activities of daily living), and resting and task-related EEG recordings. MFT will be measured using a simple task that is well-established to elicit MFT and related signals in these groups. Prior research has shown that performance on such tasks largely overlaps in these groups. On that basis, analyses will examine whether (1) individuals with Mild Cognitive Impairment and early Alzheimer’s disease exhibit greater MFT when performing at the same level as intact individuals, and (2) whether MFT differentially relates to more complex cognitive and functional skills. If successful, the proposed research could soon lead to improved screening for clinical trials, and eventually to improved early diagnosis of Alzheimer’s disease itself. Because EEG MFT is comparatively inexpensive, accessible, and easy-to-implement, it has the potential for wide and rapid dissemination. This project is consistent with the mission of the National Institute on Aging.

项目概要/摘要 该项目的主要目标是检查与任务相关的脑电图活动的特定形式，作为 早期阿尔茨海默病的潜在新型生物标志物。 尽管最近在开发阿尔茨海默病生物标志物方面取得了进展，但现有的一套 措施面临着侵入性、成本、高技术要求和低等方面的限制。 可达性。为了帮助应对这些挑战，该项目将研究脑电图中额叶 theta power (MFT)，作为一种潜在的廉价、非侵入性且易于实施的方法 选择。有人提出，由于阿尔茨海默病涉及认知和功能丧失 神经储备，早期阶段的个体需要增加脑力消耗以达到 给定的任务绩效水平。反过来，脑电图 MFT 与脑力消耗密切相关， 因此，在阿尔茨海默病的早期阶段可能会过度激活。 为了评估 MFT 作为早期阿尔茨海默病脑力消耗生物标志物的潜力， 该项目将招募三组老年人（每组 40 人；65 岁或以上；50% 女性）认知完好，或符合遗忘轻度认知的诊断标准 损伤或早期阿尔茨海默病。该项目的第一个目标是检查 MFT 跨越这三个组，同时控制任务绩效的差异。这 该项目的第二个目的是检查 MFT 对特定认知和认知缺陷的敏感性 在疾病早期阶段往往会受到影响的功能技能。 为了实现这些目标，参与者将完成一个为期三小时的学习课程，其中包括 简短的诊断电池，认知和功能技能的评估（工具活动） 日常生活）以及休息和任务相关的脑电图记录。 MFT 将使用一个简单的方法来测量 已确立的任务可以在这些组中引发 MFT 和相关信号。先前的研究有 结果表明，这些组中此类任务的表现在很大程度上是重叠的。在此基础上分析 将检查是否 (1) 患有轻度认知障碍和早期阿尔茨海默病的个体 当表现出与完整个体相同的水平时，疾病表现出更高的 MFT，并且 (2) MFT 是否与更复杂的认知和功能技能存在差异相关。 如果成功，拟议的研究可能很快就会改善临床试验的筛选， 并最终改善阿尔茨海默病本身的早期诊断。因为脑电图 MFT 是 相对便宜、易于获取且易于实施，它具有广泛应用的潜力 快速传播。该项目与国家老龄化研究所的使命一致。